2025 Annual Results Strong Revenue Growth in 2025: up 14% with Subscriptions up 20% Record Profitability: EBITDA up 22% to €13.4 million, Representing 22% of Revenue (+2 pts) Operating Leverage Confirmed: Net Profit of €9.0 million, up 14% March 30, 2026 | Sidetrade (Euronext Growth: ALBFR), the AI platform dedicated to Order-to-Cash, today announces its 2025 annual results, achieving a new all-time high in profitability despite a challenging macroeconomic environment: revenue growth of 14% at constant currency (12% on reported basis), EBITDA up 22% to €13.4 million, representing 22% of revenue, and net profit of €9.0 million (14%).Sidetrade (€m) 2025 2024 VariationRevenue 61.4 55.0 +12%of which Subscriptions 53,5 45,5 +18%Gross Margin 47.4 43.1 +10%as a % of Revenue 77% 78%         EBITDA* 13.4 11.0 +22%as a %...

IRVING, Texas, March 30, 2026 (GLOBE NEWSWIRE) — XBP Global Holdings, Inc. (“XBP Global” or “the Company”) (NASDAQ: XBP), a multinational technology and services company orchestrating mission-critical systems that enable hyper-automation and digital transformation, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. Following the transformative acquisition of Exela Technologies BPA, LLC (“BPA”) in July 2025, the Company is reporting results that reflect a significant transition period. To provide a clearer view of the combined business’ performance, the Company has included pro forma metrics alongside reported GAAP results, with reconciliations to the most comparable GAAP metrics in this release, where applicable. Reported results exclude the results of our European operations (“XBP...

Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) BRISBANE, Calif., March 30, 2026 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today reported financial results for the year ended December 31, 2025, and provided a corporate update. “2025 was a transformative year for Tempest as we strengthened our pipeline with the strategic acquisition of a portfolio of next-generation CAR-T assets,” said Matt Angel, Ph.D., President and Chief...

Reports $46.8M Revenue for 2025 materially ahead of market expectations Exits 2025 at $232M ARR1 with $19.4M December MRR1 Contracted Revenue1 Underpins 2026 Growth Trajectory FY 2026 revenue guidance raised to $360 million; Reiterated 2026 exit ARR1 of $500 million  NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) — Rezolve Ai (NASDAQ: RZLV), a global leader in Agentic Commerce and AI-powered retail infrastructure, today announced its full-year 2025 results, delivering performance materially ahead of market expectations and moving the business into live, scaled global deployment. Record Revenue: Reported GAAP revenue of $46.8 million for the year. Explosive Exit Velocity: Exited 2025 with a record $19.4M December MRR, representing a $232M+ Annualized Run Rate (ARR), exceeding original guidance of $100 million. Structural Profitability:...

Signed First Binding Customer Offtake Agreement with Trafigura Received Indications of Interest for Over $1 Billion in Project Finance Provides an Update on Plans for a Final Investment Decision (“FID”) on the South West Arkansas Project (the “SWA Project”)VANCOUVER, British Columbia, March 30, 2026 (GLOBE NEWSWIRE) — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE.A: SLI), a leading near-commercial lithium company, today announced its financial and operating results for the three-month and full year periods ended December 31, 2025. “We had a busy and productive fourth quarter as we advanced and completed multiple important milestones and deliverables for the Company,” said David Park, Chief Executive Officer and Director of Standard Lithium. “We filed a positive Definitive Feasibility Study for...

First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren’s disease $75 million private placement strengthens balance sheet and supports telitacicept global clinical development Pro-forma cash and investment balance of $530.2 million as of December 31, 2025 expected to provide runway into early 2029 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update. “Over the past six months, Vor Bio repositioned the company around telitacicept and moved quickly to build momentum. We are seeing strong engagement from key opinion leaders and principal investigators,...

HANGZHOU, China, March 30, 2026 (GLOBE NEWSWIRE) — Nano Labs Ltd (Nasdaq: NA) (“we,” the “Company” or “Nano Labs”), a leading Web 3.0 infrastructure and product solution provider and crypto treasury company today announced its unaudited financial results as of December 31, 2025 and for the six months ended December 31, 2025. Second Half of 2025 Financial SummaryNet revenue increased by 18.1% to RMB18.7 million (US$2.7 million) for the second half of 2025, from RMB15.9 million in the same period of 2024. Gross loss was RMB29.1 million (US$4.1 million) for the second half of 2025, compared to a gross profit of RMB11.6 million in the same period of 2024. Gain on change in fair value of cryptocurrencies was RMB130.0 million (US$18.5 million) for the second half of 2025, compared to a loss of RMB15.7 million in the same period of 2024. Profit...

Closed upsized initial public offering in February 2026, raising $381 million in gross proceeds Completed enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4 non-small cell lung cancerMILLBRAE, Calif., March 30, 2026 (GLOBE NEWSWIRE) — Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced fourth quarter and full year 2025 financial results and provided corporate updates. “2025 was an important year of progress for Eikon’s business and clinical programs,” said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon. “With our initial public offering, and the consequent strengthening of our balance sheet, we believe we...

FY 2025 revenue of $45.1 million, an increase of 8% over 2024 International Medical Cannabis revenue increased 43% year-over-year and represented more than 50% of total revenue Increased cash balance of $10.8 Million at the end of Q4, up $0.2 million from Q3 2025 Company remains virtually debt-free, with outright ownership of two production facilities Management to Host Conference Call / Webcast on March 30th, 2026, at 10:00 am ETTORONTO, March 30, 2026 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the full year and three months ended December 31, 2025. MediPharm achieved 8% annual revenue growth in...

Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 12-month Stability Completed with New Formulation with Potential Across Non-ocular Solid Tumor Indications, Beginning with Urologic Oncology BOSTON, March 30, 2026 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided recent business highlights. “2025 has been a year of focused execution across our clinical portfolio, with significant progress in trial enrollment, highlighted by the acceleration of our global Phase...